SCHEMBL4170722

SCHEMBL4170722

CCCCc1ccsc1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 2/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
CTRC Q99895 1/20 0.34
LIPG Q9Y5X9 1/20 0.32
SKP2 Q13309 1/20 0.32
PDE4A P27815 3/20 0.32
PDE4B Q07343 3/20 0.32
PDE4C Q08493 3/20 0.32
PDE4D Q08499 3/20 0.32
PDE3B Q13370 2/20 0.32
PDE3A Q14432 2/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
ERAP1 Q9NZ08 1/20 0.32
TLR8 Q9NR97 1/20 0.32
CYP3A4 P08684 2/20 0.32
MEN1 O00255 1/20 0.32
TP53 P04637 1/20 0.32
ALOX5 P09917 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyanide SCHEMBL27546696 0.94 TYR (0.34) TYRSLC6A4SLC6A3CTRCLIPG
SCHEMBL2795698 0.94 LIPG (0.39) TYRSLC6A4SLC6A3LIPGALDH1A1
SCHEMBL5170070 0.92 LIPG (0.42) TYRSLC6A4SLC6A3LIPGALDH1A1
SCHEMBL20338197 0.92 LIPG (0.42) TYRSLC6A4SLC6A3LIPGALDH1A1
SCHEMBL1225175 0.92 LIPG (0.42) TYRSLC6A4SLC6A3LIPGALDH1A1
SCHEMBL329220 0.92 LIPG (0.42) TYRSLC6A4SLC6A3LIPGALDH1A1
SCHEMBL19304410 0.92 LIPG (0.42) TYRSLC6A4SLC6A3LIPGALDH1A1
SCHEMBL5147986 0.92 LIPG (0.42) TYRSLC6A4SLC6A3LIPGALDH1A1
SCHEMBL198675 0.92 LIPG (0.42) TYRSLC6A4SLC6A3LIPGALDH1A1
SCHEMBL2145395 0.92 LIPG (0.42) TYRSLC6A4SLC6A3LIPGALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122059923-A Aldehyde group-guided bi (hetero) aromatic compound and synthesis method and application thereof 桂林理工大学 2026-05-19 CN disclosed
CN-103025729-B Transpirable organic semiconducting materials and the purposes in photoelectric cell thereof HELIATEK GMBH (DE) 2016-05-25 CN disclosed
US-9127020-B2 Evaporable organic semiconductive material and use thereof in an optoelectronic component HELIATEK GMBH (DE) 2015-09-08 US disclosed
US-9018397-B2 Pyrrolopyrrole derivatives, their manufacture and use BASF SE (DE) 2015-04-28 US disclosed
US-9018397-B2 Pyrrolopyrrole derivatives, their manufacture and use BASF SE (DE) 2015-04-28 US disclosed
EP-2483267-B9 EVAPORABLE ORGANICALLY SEMICONDUCTIVE MATERIAL AND USE THEREOF IN AN OPTOELECTRONIC COMPONENT HELIATEK GMBH (DE) 2014-05-14 EP disclosed
EP-2483267-B9 EVAPORABLE ORGANICALLY SEMICONDUCTIVE MATERIAL AND USE THEREOF IN AN OPTOELECTRONIC COMPONENT HELIATEK GMBH (DE) 2014-05-14 EP disclosed
EP-2483267-B1 EVAPORABLE ORGANICALLY SEMICONDUCTIVE MATERIAL AND USE THEREOF IN AN OPTOELECTRONIC COMPONENT HELIATEK GMBH (DE) 2013-08-28 EP disclosed
EP-2483267-B1 EVAPORABLE ORGANICALLY SEMICONDUCTIVE MATERIAL AND USE THEREOF IN AN OPTOELECTRONIC COMPONENT HELIATEK GMBH (DE) 2013-08-28 EP disclosed
US-20130172575-A1 Pyrrolopyrrole derivatives, their manufacture and use BASF SE (DE) 2013-07-04 US disclosed
US-20030216388-A1 Cyclocarbamate derivatives as progesterone receptor modulators WYETH 2003-11-20 US disclosed
US-6566358-B2 1,4-dihydro-benzo(d)oxazin-2-one derivatives useful for treating hormone-dependent neoplastic disease is selected from uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy, carcinomas, and adenocarcinoma WYETH 2003-05-20 US disclosed
US-20030045511-A1 Combination regimens using progesterone receptor modulators WYETH 2003-03-06 US disclosed
US-6509334-B1 This invention relates to compounds that antagonists of the progesterone receptor, their preparation and utility. Intracellular receptors (IR) form a class of structurally related gene regulators known as \"ligand dependent AMERICAN HOME PRODUCTS CORPORATION 2003-01-21 US disclosed
US-6444668-B1 IN COMBINATION WITH A PROGESTIN, AN ESTROGEN, OR BOTH; ANTIPROGESTIN IS A 1,4-DIHYDRO-BENZO(D)(1.3)OXAZIN-2-ONE WYETH 2002-09-03 US disclosed
US-20020049204-A1 Cyclocarbamate derivatives as progesterone receptor modulators WYETH 2002-04-25 US disclosed
EP-1173426-A1 CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS American Home Products Corporation (US) 2002-01-23 EP disclosed
EP-1173210-A1 CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC American Home Products Corporation (US) 2002-01-23 EP disclosed
WO-2000066571-A1 CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-11-09 WO disclosed
WO-2000066164-A1 CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC AMERICAN HOME PRODUCTS CORPORATION (US) 2000-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045511-A1 Combination regimens using progesterone receptor modulators GNRHR, PGR, PRLHR TYR 4657/4885SLC6A4 1570/4885SLC6A3 1697/4885
US-20030216388-A1 Cyclocarbamate derivatives as progesterone receptor modulators NR3C2, NR5A1, PGR TYR 4844/4885SLC6A4 2154/4885SLC6A3 2009/4885
US-20020049204-A1 Cyclocarbamate derivatives as progesterone receptor modulators NR3C1, NR5A1, CNR1 TYR 4788/4885SLC6A4 2071/4885SLC6A3 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.